NEW YORK (TheStreet) -- Sequenom, Inc. (SQNM) shares finished trading Monday up 9.1% to $3.34 following news that the company gained pre-market FDA clearance for its IMPACT genotyping test.

The noninvasive prenatel test analyzes chromosonal material in cell free DNA for pregnant women at an increased risk for fetal chromosonal abnormalities.

The San Diego-based company formed a licencing agreement with Quest Diagnostics (DGX) -- expected to make the test available by the third quarter-- to expand patient access to the test.

Must ReadWarren Buffett's 25 Favorite Stocks 

SQNM Chart

SQNM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

IBM Shares Jump After Beating Earnings and Guidance Expectations

IBM Shares Jump After Beating Earnings and Guidance Expectations

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

Tesla's Biggest Near-Term Headwind, According to Analyst

Tesla's Biggest Near-Term Headwind, According to Analyst

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

New Trend for Gap Stock Is Down

New Trend for Gap Stock Is Down